Praxis Bioresearch Expands its Board of Directors with Appointment of Adam Levy LOS ANGELES, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Praxis Bioresearch (“Praxis”), a biopharmaceutical company focused on the discovery and development of therapeutics for chronic neuropsychiatric and...

Praxis Bioresearch Presents Phase 0 Clinical Data for PRX-P4-003 at 14th Annual CTAD conference LOS ANGELES, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Praxis Bioresearch reports Clinical Phase 0 study data (PBR001) to demonstrate the desired pharmacokinetic profile for its lead product candidate,...

Praxis Bioresearch Awarded $2.9 Million Fast-Track SBIR Grant for Development of Novel Therapy for Apathy in Alzheimer’s Disease LOS ANGELES, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Praxis is proud to announce to be the recipient of a Fast-Track SBIR award to develop treatment for apathy in Alzheimer’s Disease. The award, in its...

Praxis Bioresearch Announces Positive Results from Clinical Microdose Study in Humans Showing Oral Activation of Its Novel Prodrug Stimulant PRX-P4-003 All subjects who were dosed with Prodrug PRX-P4-003 had systemic exposure of the active moiety (-)-fencamfamine suggesting robust intestinal conversionAs anticipated, fed subjects showed earlier...

Praxis Bioresearch Announces Issuance of U.S. Patent on its Prodrug Stimulant PRX-P4-003 SACRAMENTO, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Praxis Bioresearch, a biopharmaceutical company focused on the discovery and development of novel therapeutics for chronic central nervous...